The use of synthetic peptides, often taken by injection for health and longevity benefits, is gaining popularity, but the FDA has raised concerns about their efficacy and safety. Despite their promotion online, many peptides, including BPC-157, TB-500, and MOTs-C, lack robust clinical trial evidence.
Health Secretary Robert F. Kennedy Jr. is advocating for relaxed regulations on these therapies, although FDA scientists recommend stricter controls due to safety concerns and insufficient data. Following regulatory changes in 2023, peptide users have turned to gray markets for supplies.
A committee will evaluate the evidence supporting specific uses of these peptides for various health issues, but previous findings indicate insufficient proof to warrant changes in their classification. Many medical professionals, like Dr. Alexander Weber, echo these concerns, noting that patients frequently inquire about peptides without clear supporting data.
Source link
